Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709333 | 0.94 | MEN1 (0.47) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL3441805 | 0.92 | MEN1 (0.43) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL4294627 | 0.90 | MEN1 (0.46) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL701128 | 0.88 | MEN1 (0.45) | MEN1KMT2AEPHX2ALDH1A1LMNA | |
| SCHEMBL707423 | 0.84 | MEN1 (0.46) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL700251 | 0.84 | CCR5 (0.57) | LMNACCR5OPRD1 | |
| SCHEMBL4430198 | 0.82 | MEN1 (0.43) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL4444361 | 0.82 | MEN1 (0.42) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL710728 | 0.81 | MEN1 (0.47) | MEN1KMT2AOPRM1EPHX2ALDH1A1 | |
| SCHEMBL698464 | 0.81 | MEN1 (0.46) | MEN1KMT2AEPHX2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | MEN1 3536/4885KMT2A 3631/4885OPRM1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.